Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 3/20 | 0.49 |
| ▸ | L3MBTL3 | Q96JM7 | 10/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.42 |
| ▸ | FLT3 | P36888 | 2/20 | 0.40 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.40 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.40 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30183353 | 1.00 | ATR (0.49) | ATRL3MBTL3L3MBTL1FLT3MBTD1 | |
| SCHEMBL30183153 | 0.99 | ATR (0.49) | ATRL3MBTL3L3MBTL1FLT3MBTD1 | |
| SCHEMBL20649115 | 0.99 | ATR (0.49) | ATRL3MBTL3L3MBTL1FLT3MBTD1 | |
| SCHEMBL20648981 | 0.95 | FLT3 (0.44) | ATRL3MBTL3L3MBTL1FLT3CCNA2 | |
| SCHEMBL30183427 | 0.95 | FLT3 (0.44) | ATRL3MBTL3L3MBTL1FLT3CCNA2 | |
| SCHEMBL20649143 | 0.94 | ATR (0.43) | ATRL3MBTL3L3MBTL1FLT3CCNA2 | |
| SCHEMBL30183423 | 0.94 | ATR (0.43) | ATRL3MBTL3L3MBTL1FLT3CCNA2 | |
| SCHEMBL20649120 | 0.94 | EPHX2 (0.44) | ATRL3MBTL3L3MBTL1FLT3PIK3CA | |
| SCHEMBL30183354 | 0.94 | EPHX2 (0.44) | ATRL3MBTL3L3MBTL1FLT3PIK3CA | |
| SCHEMBL21875626 | 0.93 | ATR (0.42) | ATRL3MBTL3L3MBTL1FLT3CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110997678-B | Pyrazoloquinazoline derivatives as choline kinase inhibitors | 内尔维亚诺医疗科学公司 | 2023-02-21 | — | — | CN | claimed |
| US-11117901-B2 | Substituted pyrazolo[4,3-h]quinazolines as choline kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2021-09-14 | — | — | US | claimed |
| US-20200131188-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2020-04-30 | — | — | US | claimed |
| CN-110997678-A | Pyrazoloquinazoline derivatives as choline kinase inhibitors | 内尔维亚诺医疗科学公司 | 2020-04-10 | — | — | CN | claimed |
| CN-110997678-B | Pyrazoloquinazoline derivatives as choline kinase inhibitors | 内尔维亚诺医疗科学公司 | 2023-02-21 | — | — | CN | disclosed |
| US-11117901-B2 | Substituted pyrazolo[4,3-h]quinazolines as choline kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2021-09-14 | — | — | US | disclosed |
| US-11117901-B2 | Substituted pyrazolo[4,3-h]quinazolines as choline kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2021-09-14 | — | — | US | disclosed |
| US-20200131188-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2020-04-30 | — | — | US | disclosed |
| US-20200131188-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2020-04-30 | — | — | US | disclosed |
| CN-110997678-A | Pyrazoloquinazoline derivatives as choline kinase inhibitors | 内尔维亚诺医疗科学公司 | 2020-04-10 | — | — | CN | disclosed |
| WO-2019011715-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131188-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | CHKA, CHKB, NADK | ATR 599/4885L3MBTL3 3987/4885L3MBTL1 3844/4885 |
| US-11117901-B2 | Substituted pyrazolo[4,3-h]quinazolines as choline kinase inhibitors | CHKA, CHKB, NADK | ATR 621/4885L3MBTL3 4034/4885L3MBTL1 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.